PCI Biotech interim first-half year 2022 results
August 31, 2022 01:00 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 31 August 2022 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim first-half year 2022 results. Please find enclosed the report and...
Central Nervous System Biomarkers Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)
June 10, 2022 07:05 ET
|
ReportLinker
New York, June 10, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Central Nervous System Biomarkers Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 -...
Processa Pharmaceuticals Announces Year-End 2021 Results and Provides Corporate Update
March 30, 2022 16:00 ET
|
Processa Pharmaceuticals, Inc.
Targeting Major Milestones 2022 HANOVER, Md., March 30, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage company developing...
Bioasis Technologies Inc. and Aposense Enter into a Research Collaboration
March 31, 2021 16:05 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., March 31, 2021 (GLOBE NEWSWIRE) -- Bioasis Technologies Inc. (TSXV:BTI; OTCQB:BIOAF), (“Bioasis” or the “Company”), a pre-clinical, research-stage biopharmaceutical company...
Processa Pharmaceuticals Announces Year end 2020 Results and Provides Corporate Update
March 25, 2021 16:06 ET
|
Processa Pharmaceuticals, Inc.
Clinical drug pipeline is funded and targeting major milestones in 2021 HANOVER, Md., March 25, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"),...
PROCESSA PHARMACEUTICALS ANNOUNCES THAT IT HAS ENTERED INTO AN AGREEMENT WITH APOSENSE, LTD TO LICENSE IN THE NEXT GENERATION IRINOTECAN DRUG
June 01, 2020 09:30 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, June 01, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA) announced today that it has signed an agreement with Aposense, LTD. to license in the patent rights and...
Global Central Nervous System Biomarkers Market (2020 to 2025) - Growth, Trends, and Forecast
May 05, 2020 06:03 ET
|
Research and Markets
Dublin, May 05, 2020 (GLOBE NEWSWIRE) -- The "Central Nervous System Biomarkers Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's ...
IBA SA reports improved 2012 operating results. Net result impacted by legacy Issues.
March 18, 2013 02:00 ET
|
IBA SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} IBA reports improved 2012 operating results. Net...
CEO of the Tel-Aviv Stock Exchange to Ring The NASDAQ Stock Market Opening Bell to Commence the 5th TASE and NASDAQ Investor Conference at NASDAQ MarketSite
May 16, 2012 10:00 ET
|
Nasdaq, Inc.
ADVISORY, May 16, 2012 (GLOBE NEWSWIRE) --
What:
Ester Levanon, Chief Executive Officer ofthe Tel-Aviv Stock Exchange will preside over The NASDAQ Stock Market Opening Bell to officially...
Aposense Cancer Drug Demonstrates 100% Oral Bioavailability in New Study
September 06, 2011 07:30 ET
|
Aposense
PETACH-TIKVA, ISRAEL--(Marketwire - Sep 6, 2011) - Aposense Ltd. (TELAVIV: APOS), a world leader in developing diagnostic and therapeutic drugs based on in vivo targeting of apoptosis (programmed...